Patients with AL amyloidosis and low free light-chain burden have distinct clinical features and outcome

Amyloid. 2017 Mar;24(sup1):64-65. doi: 10.1080/13506129.2017.1293517.

Authors

Paolo Milani¹, Marco Basset¹, Francesca Russo¹, Andrea Foli¹, Francesca Lavatelli¹, Mario Nuvolone¹, Giovanni Ferraro¹, Giovanni Palladini¹, Giampaolo Merlini¹

Affiliation

¹ a Amyloidosis Research and Treatment Center, Foundation Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, and Department of Molecular Medicine, University of Pavia , Pavia , Italy.

PMID: 28434343
DOI: 10.1080/13506129.2017.1293517

No abstract available

Publication types

Letter

MeSH terms

Aged
Antimetabolites, Antineoplastic / therapeutic use
Female
Humans
Immunoglobulin Light Chains / blood*
Immunoglobulin Light-chain Amyloidosis / drug therapy
Immunoglobulin Light-chain Amyloidosis / immunology
Immunoglobulin Light-chain Amyloidosis / mortality
Immunoglobulin Light-chain Amyloidosis / pathology*
Male
Middle Aged
Patient Selection
Plasma Cells / drug effects
Plasma Cells / immunology*
Plasma Cells / pathology
Prospective Studies
Survival Analysis

Substances

Antimetabolites, Antineoplastic
Immunoglobulin Light Chains